Cell death pathology: Perspective for human diseases

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 451-455

  Agostini, Massimiliano ^a   Tucci, Paola ^a,b,c   Melino, Gerry ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

Author keywords

AIDS; Apoptosis; Cancer; Immune system; Neurodegenerative diseases

Indexed keywords

AEG 35156; AMIFOSTINE; AT 406; BETULIC ACID; CLADRIBINE; CONTUSUGENE LADENOVEC; EPOXOMICIN; GATAPARSEN; LONIDAMINE; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; OBLIMERSEN; ONYX 015; PRO1762; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN CD95; RECOMBINANT SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SCH 58500; TRAIL RECEPTOR 1 MONOCLONAL ANTIBODY; TRAIL RECEPTOR 2 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VERTEPORFIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOPHAGY; CANCER INVASION; CARCINOMA; CELL DEATH; DEGENERATIVE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; LYMPHOMA; METASTASIS; MYELOMA; NEOPLASM; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SARCOMA; SHORT SURVEY;

APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM DISEASES; NEURODEGENERATIVE DISEASES;

EID: 80054884802     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.081     Document Type: Short Survey

References (90)

1. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26:239-257.
2. Kroemer G., Galluzzi L., Vandenabeele P., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
3. Sassone J., Colciago C., Marchi P., et al. Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3). Cell Death Dis. 2010, 1:e7.
4. Engel T., Tanaka K., Jimenez-Mateos E.M., et al. Loss of p53 results in protracted electrographic seizures and development of an aggravated epileptic phenotype following status epilepticus. Cell Death Dis. 2010, 1:e79.
5. Di Guardo G., Marruchella G. Prions and neuronal death. Cell Death Dis 2010, 1:e6.
6. Calandrella N., De Seta C., Scarsella G., Risuleo G. Carnitine reduces the lipoperoxidative damage of the membrane and apoptosis after induction of cell stress in experimental glaucoma. Cell Death Dis. 2010, 1:e62.
7. Almasieh M., Zhou Y., Kelly M.E., Casanova C., Di Polo A. Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis. 2010, 1:e27.
8. Perrone L., Devi T.S., Hosoya K.I., Terasaki T., Singh L.P. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010, 1:e65.
9. Sancho-Pelluz J., Alavi M.V., Sahaboglu A., et al. Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death Dis. 2010, 1:e24.
10. Ca channels. Cell Death Dis. 2010, 1:e13.
11. Francis K.R., Wei L. Human embryonic stem cell neural differentiation and enhanced cell survival promoted by hypoxic preconditioning. Cell Death Dis. 2010, 1:e22.
12. Degli Esposti M. Bcl-2 antagonists and cancer: from the clinic back to the bench. Cell Death Dis. 2010, 1:e37.
13. Reis C.R., van der Sloot A.M., Natoni A., et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 2010, 1:e83.
14. Schneider-Jakob S., Corazza N., Badmann A., et al. Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Dis. 2010, 1:e86.
15. Rigaud O., Fortunel N.O., Vaigot P., et al. Exploring ultrashort high-energy electron-induced damage in human carcinoma cells. Cell Death Dis. 2010, 1:e73.
16. Sättler M.B., Bähr M. Future neuroprotective strategies. Exp. Neurol. 2010, 225:40-47.
17. Li Q., Li H., Roughtonet K., et al. Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell Death Dis. 2010, 1:e56.
18. Fischer U., Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death and Differentiation 2005, 12:942-961.
19. Reed Drug J.C. Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 2006, 3:388-398.
20. Reed J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 2002, 1:111-121.
21. Liang C. Negative regulation of autophagy. Cell Death Diff. 2010, 17:1807-1815.
22. Delgado M.A., Deretic V. Toll-like receptors in control of immunological autophagy. Cell Death Diff. 2009, 16:976-983.
23. Noda T., Fujita N., Yoshimori T. The late stages of autophagy: how does the end begin?. Cell Death Diff. 2009, 16:984-990.
24. Longatti A., Tooze S.A. Vesicular trafficking and autophagosome formation. Cell Death Diff. 2009, 16:956-965.
25. Eisenberg-Lerner A., Bialik S., Simon H.U., Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Diff. 2009, 16:966-975.
26. Vellai T. Autophagy genes and ageing. Cell Death Diff. 2009, 16:94-102.
27. Kourtis N., Tavernarakis N. Autophagy and cell death in model organisms. Cell Death Diff. 2009, 16:21-30.
28. Maiuri M.C., Tasdemir E., Criollo A., et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Diff. 2009, 16:87-93.
29. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
30. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
31. Tait S.W., Green D.R. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008, 27:6452-6461.
32. Fricker M., O'Prey J., Tolkovsky A.M., Ryan K.M. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis. 2010, 1:e59.
33. Goldberg M.S., Xing D., Ren Y., et al. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108:745-750.
34. Flourakis M., Lehen'kyi V., Beck B., et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis. 2010, 1:e75.
35. Bhatnagar N., Li X., Padi S.K.R., Zhang Q., Tang M.-S., Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1:e105.
36. Wang Y., Nangia-Makker P., Balan V., Hogan V., Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis. 2010, 1:e101.
37. Fenouille N., Puissant A., Dufies M., et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010, 70:9659-9670.
38. Accordi B., Espina V., Giordan V.M., et al. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One 2010, 5:e13552.
39. Heidari N., Hicks M.A., Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis. 2010, 1:e76.
40. Wemeau M., Kepp O., Tesnière A., et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010, 1:e104.
41. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
42. Ramadan S., Terrinoni A., Catani M.V., et al. p73 induces apoptosis by different mechanisms. Biochem. Biophys. Res. Commun. 2005, 331:713-717.
43. Schilling T., Kairat A., Melino G., et al. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2010, 394:817-823.
44. Schilling T., Schleithoff E.S., Kairat A., et al. Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem. Biophys. Res. Commun. 2009, 387:399-404.
45. Melino G., De Laurenzi V., Vousden K.H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2002, 2:605-615.
46. Melino G., Bernassola F., Ranalli M., et al. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J. Biol. Chem. 2004, 279:8076-8083.
47. Gong J.G., Costanzo A., Yang H.Q., et al. Regulation of the p53 homolog p73 by c-Abl tyrosine kinase in cell death response to cisplatin. Nature 1999, 399:806-809.
48. Tanner C.M., Ottman R., Goldman S.M., et al. Parkinson disease in twins: an etiologic study. JAMA 1999, 281:341-346.
49. Hutton M., Perez-Tur J., Hardy J. Genetics of Alzheimer's disease. Essays Biochem. 1998, 33:117-131.
50. Kurtland L.T. Amyotrophic lateral sclerosis and Parkinson's disease complex on Guam linked to an environmental neurotoxin. Trends Neurosci. 1988, 11:51-54.
51. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neuro. Res. 2001, 1:407-418.
52. Tanner C.M. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 1989, 12:49-54.
53. Corona C., Masciopinto F., Silvestri E., et al. Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis. 2010, 1:e91.
54. Martin J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 1999, 340:1970-1980.
55. Dribben W.H., Eisenman L.N., Mennerick S. Magnesium induces neuronal apoptosis by suppressing excitability. Cell Death Dis. 2010, 1:e63.
56. Nicolai J., Burbassi S., Rubin J., Meucci O. CXCL12 inhibits expression of the NMDA receptor's NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. Cell Death Dis. 2010, 1:e33.
57. Masters C.L., Simms G., Weinman N.A., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82:4245-4249.
58. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
59. Lee M.-H., Lin S.-R., Chang J.-Y., et al. TGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease. Cell Death Dis. 2010, 1:e110.
60. Avila J. Alzheimer disease: caspases first. Nat. Rev. Neurol. 2010, 6:587-588.
61. D'Amelio M., Cavallucci V., Middei S., et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 2011, 14:69-76.
62. Sivananthan S.N., Lee A.W., Goodyer C.G., LeBlanc A.C. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid β-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death Dis. 2010, 1:e100.
63. Rodríguez J.J., Witton J., Olabarria M., Noristani H.N., Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death Dis. 2010, 1:e1.
64. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
65. Athanassiadou A., Voutsinas G., Psiouri L., et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 1999, 65:555-558.
66. Singleton A.B., Farrer M., Johnson A., et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
67. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002, 926:42-50.
68. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H., et al. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol. 2002, 61:245-253.
69. T.A. Yacoubian, S.R. Slone, A.J. Harrington, et al., Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease, Cell Death Dis. 1 (2010) e2.
70. Wu J.S., Cheung W.M., Tsai Y.S., et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3epsilon upregulation. Circulation 2009, 119:1124-1134.
71. Haughey N.J., Nath A., Chan S.L., Borchard A.C., Rao M.S., et al. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J. Neurochem. 2002, 83:1509-1524.
72. Killick R., Niklison-Chirou M., Tomasini M.R., et al. P73: a multifunctional protein in neurobiology. Mol. Neurobiol. 2011, 43:139-146.
73. A. Rufini, M. Agostini, F. Grespi, et al., p73 in Cancer Genes, Cancer. 2 (2011) 491-502.
74. Wilson C., Henry S., Smith M.A., Bowser R. The p53 homologue p73 accumulates in the nucleus and localizes to neurites and neurofibrillary tangles in Alzheimer disease brain. Neuropathol. Appl. Neurobiol. 2004, 30:19-29.
75. Scacchi R., Gambina G., Moretto G., Corbo R.M. Association study between P53 and P73 gene polymorphisms and the sporadic late-onset form of Alzheimer's disease. J. Neural. Transm. 2009, 116:1179-1184.
76. Hooper C., Killick R., Tavassoli M., Melino G., Lovestone S. TAp73alpha induces tau phosphorylation in HEK293a cells via a transcription-dependent mechanism. Neurosci Lett. 2006, 401:30-34.
77. Wetzel M.K., Naska S., Laliberté C.L., et al. p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease. Neuron 2008, 11:708-721.
78. Agostini M., Tucci P., Chen H., et al. p73 regulates maintenance of neural stem cell. Biochem. Biophys. Res. Commun. 2010, 403:13-17.
79. F. Talos, A. Abraham, A.V. Vaseva, et al., p73 Is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis, Cell Death Differ. 17 (2010) 1816-1829.
80. Fujitani M., Cancino G.I., Dugani C.B., et al. TAp73 acts via the bHLH Hey2 to promote long-term maintenance of neural precursors. Curr. Biol. 2010, 20:2058-2065.
81. L. González-Cano, M. Herreros-Villanueva, R. Fernandez-Alonso, et al., p73 deficiency results in impaired self renewal and premature neuronal differentiation of mouse neural progenitors independently of p53. Cell Death Dis. 1 (2010) e109.
82. Cohen J.J. Programmed cell death in the immune system. Adv. Immunol. 1991, 50:55-85.
83. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
84. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
85. Krammer P.H. CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
86. D. Tischner, C. Woess, E. Ottina. A. Villunger, Bcl-2-regulated cell death signalling in the prevention of autoimmunity, Cell Death Dis. 1 (2010) e48.
87. Maag R.S., Mancini M., Rosen A., Machamer C.E. Caspase-resistant golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol. Biol. Cell 2005, 16:3019-3027.
88. J.P.X. Cheng, V.M.S. Betin, H. Weir, et al., Caspase cleavage of the Golgi stacking factor GRASP65 is required for Fas/CD95-mediated apoptosis, Cell Death Dis. 1 (2010) e82.
89. Rothen M., Gratzl S., Hirsch H.H., Moroni C. Apoptosis in HIV-infected individuals is an early marker occurring independently of high viremia. AIDS Res. Hum. Retroviruses 1997, 13:771-779.
90. N.W. Cummins, A.D. Badley, Mechanisms of HIV-associated lymphocyte apoptosis, Cell Death Dis. 1 (2010) e99.